Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPHIARE obexelimab study in warm autoimmune hemolytic anemia
jRCT2021230052Phase 3Completed
- Sponsor
- Zenas BioPharma
- Start
- Feb 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of obexelimab in warm autoimmune hemolytic anemia (wAIHA) (4 arms), sponsored by Zenas BioPharma. Started Feb 2024; status: completed.
02
Drugs
obexelimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on jRCT2021230052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230052.